Market Trends of Global Helicobacter Pylori Diagnostics Industry
This section covers the major market trends shaping the Helicobacter Pylori Diagnostics Market according to our research experts:
Immunoassay Segment is Expected to Witness Growth Over the Forecast Period
An immunoassay is a test that relies on biochemistry to measure the presence and concentration of an analyte. The analyte can be large proteins, antibodies that a person has produced as a result of an infection, or small molecules. Immunoassays are highly sensitive and specific. Their high specificity results from the use of antibodies and purified antigens as reagents. This assay can be used for the diagnosis of a disease directly, by measuring the presence of antigens. In addition, it is a highly selective bioanalytical method that measures the presence or concentration of analytes ranging from small molecules to macromolecules in solution using an antibody or antigen as a biorecognition agent.
The immunoassay segment holds a significant market share in the helicobacter pylori diagnostics market and is anticipated to show a similar trend over the forecast period due to the presence of several advanced technologies such as the enzyme immunoassays which are used for the detection of antibodies. The rising prevalence of Helicobacter pylori infections and gastritis and technological advancements are the key driving factors in the immunoassay segment. For instance, as per the study titled, "Diagnosis of Helicobacter pylori Infection and Recent Advances" published in August 2021, the prevalence of gastritis was around 50.0%, which was shown from 40.7% to 56.0% and it included 20.0%-30.0% of chronic atrophic gastritis, globally in 2021. It also reported that Helicobacter pylori infection is generally consistent with the prevalence of gastritis and Helicobacter pylori positive gastritis generally accounts for more than 80.0%. Immunoassays are generally used for the detection of such infections, therefore, increasing cases of Helicobacter pylori infection and gastritis are anticipated to propel the segment growth over the forecast period.
North America is Expected to Dominate the Helicobacter Pylori Diagnostics Market
North America is expected to dominate the overall helicobacter pylori diagnostics market over the forecast period. The growth is due to factors such as the increasing number of cases of infectious diseases, increasing awareness of infectious diseases, and new product launches. For instance, in June 2021, Biomerica Inc. announced that it has signed an exclusive five-year distribution agreement with a Canadian partner for the distribution and marketing of Biomerica's new and proprietary Helicobacter pylori test, called hp+detect. The hp+detect product has been developed for the identification and monitoring of helicobacter pylori infection, the leading cause of duodenal and gastric ulcers, and a contributing risk factor associated with gastric cancer. Therefore, such instances are anticipated to propel market growth in the North America region.
Key product launches, high concentration of market players or manufacturer's presence, and acquisition & partnerships among major players, and increasing cases of gastrointestinal disorders in the United States are some of the factors driving the growth of the Helicobacter pylori diagnostics market in the country. For instance, as per the journal published by the Cleveland Clinic Organization in September 2020, acute gastritis affects about 8 out of every 1,000 people in the United States every year. It also reported that chronic, long-term gastritis is less common and it affects approximately 2 out of 10,000 people in the United States every year.
Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the North America Region.
